Sugi Predict

Sugi Predict / Compounds / SCHEMBL6017704

SCHEMBL6017704

SCHEMBL6017704

CCCCC[Si](CCCCC)(CCCCC)O[Si](CCCCC)(CCCCC)CCCCC

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.41
▸ THRB P10828 1/20 0.41
▸ LMNA P02545 4/20 0.35
▸ SLC22A1 O15245 3/20 0.33
▸ SLC22A2 O15244 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ FAAH O00519 1/20 0.32
▸ DNM1 Q05193 5/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4959288 0.97 TSHR (0.47) TSHRTHRBLMNASLC22A1DNM1
SCHEMBL7036618 0.97 TSHR (0.47) TSHRTHRBLMNASLC22A1DNM1
SCHEMBL9859881 0.97 TSHR (0.47) TSHRTHRBLMNASLC22A1DNM1
SCHEMBL11024773 0.97 TSHR (0.47) TSHRTHRBLMNASLC22A1DNM1
SCHEMBL18528250 0.94 TSHR (0.44) TSHRTHRBLMNASLC22A1DNM1
SCHEMBL5940456 0.90 TSHR (0.38) TSHRTHRBLMNAALDH1A1
SCHEMBL8409898 0.87 DNM1 (0.48) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL17088158 0.85 TSHR (0.33) TSHRTHRBLMNA
SCHEMBL23781420 0.84 TSHR (0.40) TSHRTHRBLMNAFAAHDNM1
SCHEMBL613246 0.79 LMNA (0.40) TSHRTHRBLMNASLC22A1SLC22A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3838901-B1 COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES IRIMAJIRI THERAPEUTICS INC (JP) 2023-09-27 — — EP claimed
EP-0311371-A2 Cationically curable compositions LOCTITE (IRELAND) Ltd. (IE) 1989-04-12 — — EP claimed
WO-2024096066-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE 第一工業製薬株式会社 2024-05-10 — — WO disclosed
WO-2024096067-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN 第一工業製薬株式会社 2024-05-10 — — WO disclosed
EP-4361148-A1 HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE Albius Sciences Alpha Private Limited (SG) 2024-05-01 — — EP disclosed
WO-2024071371-A1 HETEROCYCLIC COMPOUND ユビエンス株式会社 2024-04-04 — — WO disclosed
WO-2024071370-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE 第一工業製薬株式会社 2024-04-04 — — WO disclosed
CN-117730079-A Heterocyclyl-substituted polyheterazoles derivatives as medicaments for the treatment and/or prophylaxis of RSV infections 亚博思生物科技(第一)有限公司 2024-03-19 — — CN disclosed
WO-2024029630-A1 CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION 第一工業製薬株式会社 2024-02-08 — — WO disclosed
EP-4261830-A1 NOVEL PEPTIDOMIMETIC COMPOUND AND DESIGN Oita University Institute of Advanced Medicine, Inc. (JP) 2023-10-18 — — EP disclosed
US-11780841-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same IRIMAJIRI THERAPEUTICS INC. (JP) 2023-10-10 — — US disclosed
WO-2020036211-A1 COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES 株式会社大分大学先端医学研究所 2020-02-20 — — WO disclosed
US-6998179-B2 Process for preparing a K-type polarizer 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-02-14 — — US disclosed
US-20040241480-A1 Process for preparing a K-type polarizer 3M INNOVATIVE PROPERTIES COMPANY 2004-12-02 — — US disclosed
EP-1476772-A1 PROCESS FOR PREPARING A K-TYPE POLARIZER 3M Innovative Properties Company (US) 2004-11-17 — — EP disclosed
US-6808657-B2 EXPOSING A PRE-POLARIZING ARTICLE TO RADIANT ENERGY, PRE-POLARIZING ARTICLE COMPRISING A UNIAXIALLY ORIENTED VINYLALCOHOL POLYMER FILM LAYER, AND AN ACID DONOR LAYER COMPRISING A PHOTOACID GENERATOR 3M INNOVATIVE PROPERTIES COMPANY 2004-10-26 — — US disclosed
US-20030157353-A1 Process for preparing a K-type polarizer 3M INNOVATIVE PROPERTIES COMPANY 2003-08-21 — — US disclosed
WO-2003069382-A1 PROCESS FOR PREPARING A K-TYPE POLARIZER 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-08-21 — — WO disclosed
EP-1070052-A1 FUNGICIDE COMPOSITIONS COMPRISING A HYDROXIMIC OR HYDRAZONIC GROUP AVENTIS CROPSCIENCE S.A. (FR) 2001-01-24 — — EP disclosed
WO-1999051579-A1 FUNGICIDE COMPOSITIONS COMPRISING A HYDROXIMIC OR HYDRAZONIC GROUP AVENTIS CROPSCIENCE S.A. (FR) 1999-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780841-B2 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same AVPR1B, AVPR2, F12 TSHR 3098/4885THRB 2707/4885LMNA 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.